# Medicare Opens First Obesity Coverage as Lilly Hits Record High - Healthcare Podcast Weekly Digest - Week of June 27, 2026

> Healthcare was the defensive rotation trade into the second half: the XLV hit 52-week highs, Eli Lilly touched an all-time high near $1,238, Medicare launched its first-ever obesity coverage on July 1, and a record pharma M&A supercycle rolled on. Our synthesis for the week of June 27 to July 3, 2026.

## Healthcare Podcast Weekly Digest

### Week of June 27, 2026: Medicare Opens First Obesity Coverage as Lilly Hits Record High

---

## 1. Opening Summary

Healthcare was the market's defensive rotation trade into the second half, with the XLV hitting 52-week highs and Eli Lilly touching an all-time high near $1,238. Two forces dominated the conversation: the July 1 launch of Medicare's "GLP-1 Bridge" (the first-ever Medicare obesity-drug coverage) and a record pharma M&A supercycle, 32 billion-dollar deals worth ~$123B YTD, both driven by the same ~$300B patent cliff. Managed care sentiment quietly turned from bear to margin-recovery ahead of UnitedHealth's July 16 print, even as new drug-pricing and tariff policy (Section 232, Most-Favored-Nation, a Section 301 probe of Germany) hangs over the group.

## 2. Key People This Week

| Speaker | Affiliation | Key quote / view |
| --- | --- | --- |
| Liz Thomas & Caleb Silver | SoFi / Investopedia | GLP-1 market growing "10% to 12% CAGR for the next 10 years at least"; one in eight Americans now on a GLP-1. |
| Ken Cauley | IBD (Stock Market Today) | Bullish, owns Lilly, "one of the Cadillacs in its industry group." |
| David Reisinger | Leerink (via CNBC) | Medicare obesity coverage could "rake in $1 billion in annual revenue for both Lilly and Novo." |
| Tyler Crowe / Lou Whiteman / Matt Frankel | Motley Fool | "32 separate deals worth a billion dollars or more for a total deal value of $123 billion" YTD; Lilly best-run big pharma, Merck the worry. |
| Jerry Lee & Nick Richet | J.P. Morgan (co-heads healthcare IB) | XBI at five-year highs; "every single large-cap pharma is staring at a different set of LOEs." |
| Jakob Emerson | Becker's Healthcare | UnitedHealth is becoming "the Apple of healthcare," ~$3B AI spend, 1,000 AI use cases live. |
| "Vawb" | Wall Street Wildlife | Novo at "10 times earnings" vs Lilly at "40 times earnings," cheap, but a possible value trap. |
| Michael Kleinrock | IQVIA (Medicine Use Trends) | 2025 US drug spend $606B, +10.6%; GLP-1s only ~1 point of growth. |
| Ben Inker | GMO | US large-cap growth an "AI bubble," near-zero real returns, the macro case for the healthcare rotation. |

## 3. Hot Topics

**GLP-1 / obesity (the week's center of gravity).** The Lilly-Novo duopoly (~60/40 in Lilly's favor) faces both a giant catalyst and rising competition. On July 1, CMS launched the 18-month "GLP-1 Bridge" pilot: eligible seniors pay a $50/month copay for Wegovy, Zepbound and the two new oral pills (program runs through end-2027). Lilly hit an all-time high of $1,238 on 6/29 and a ~$1.06T market cap. Novo research says 75% of Medicare seniors prefer pills over injections, making the Foundayo-vs-oral-Wegovy pill battle the new front. On [The Important Part](https://app.matterfact.com/podcasts/b064a072808cf27b438a8b3e52fa273c75c630214f0c3ceddd2fe406bb9d8a8d), Liz Thomas and Caleb Silver traced the second-order winners (protein/fiber, air fryers, freezers, telehealth) and losers (CPG names like Nestlé and Mondelez).

**Eli Lilly.** Beyond GLP-1, the bull case is the pipeline (oral weight-loss, Alzheimer's, immunology, oncology, non-opioid pain) and one of the best patent-cliff profiles in the group: tirzepatide (Mounjaro/Zepbound) protected through 2036, and Evaluate projects >$70B in 2032 sales plus >$25B for the Foundayo pill ([BioSpace](https://app.matterfact.com/podcasts/d6018673b8f332c56cd6142097bc9d728abcd84099f21266aa540c289da7c12e)). Leerink's David Risinger raised his target to $1,232 from $1,119 (6/25).

**Novo Nordisk.** The bear/value debate: down ~45% over the year, ~$2.3B of buybacks, ~9,000 job cuts (~11% of workforce). February's CagriSema head-to-head loss cost ~15% in a day (~$100B market cap); a later diabetes readout beat expectations as a secondary opportunity ([Wall Street Wildlife](https://app.matterfact.com/podcasts/14b0bd73d8e86b44cf24cd4113926be17e80254ce9af4952ddbf2a5f90413033)).

**UnitedHealth.** Sentiment is repairing ahead of the July 16 Q2 print. BofA raised its target to $475 from $450 (6/24) and Morgan Stanley to $468 from $453 (6/30), arguing UNH "should set a positive tone" for managed care earnings. UNH will also cover Guardant's Shield blood-based colorectal-cancer screen for average-risk adults 45+ effective Aug 1 (~40M members), a "huge" derisking event for Guardant per BTIG ([UnitedHealthcare policy](https://www.uhcprovider.com/content/dam/provider/docs/public/policies/index/commercial/molecular-oncology-testing-for-cancer-08012026.pdf)).

**Drug-spend backdrop.** IQVIA's Michael Kleinrock: 2025 US spend hit $606B (+10.6%, after +14.4% in 2024); GLP-1s are only ~1 point of growth, the other 9.6% is spread across oncology, immunology, neurology. List-price sales were $1.363T vs $606B net, a ~$670B gross-to-net spread ([The Astonishing Healthcare Podcast](https://app.matterfact.com/podcasts/92a895591b2c4b0011c4f430beb1de8b1a282600651c06d68da204674d759336)).

## 4. Key Debates

**Novo Nordisk: value or value trap?**
- *Bull:* ~10x earnings vs Lilly's ~40x, a dividend, aggressive buybacks and cost cuts, and a still-early global market where "a lot of the bad news is baked in."
- *Bear:* Structurally second to Lilly on efficacy and pipeline; "a very, very steep downward slope … unless you had an edge, you would not buy this." Trump drug-pricing pressure hits the Danish firm harder than domestic Lilly ([Wall Street Wildlife](https://app.matterfact.com/podcasts/14b0bd73d8e86b44cf24cd4113926be17e80254ce9af4952ddbf2a5f90413033)).

**Big pharma M&A: smart re-tooling or scrambling?**
- *Bull:* Lilly is "throwing all of the cash from GLP-1s into a ton of deals" to diversify well ahead of its cliff; FDA's softer rare-disease posture is re-rating clinical-stage assets.
- *Bear:* Merck is the cautionary tale: Keytruda >50% of revenue, patent gone 2028, three deals in 10 months and "little room for error" ([Motley Fool](https://app.matterfact.com/podcasts/e6686e7e3de4d8b99adf4b0fee58ffe833c7a154b3d121b13da68d61a2174d85)).

**Managed care: margin recovery or policy overhang?**
- *Bull:* Utilization stabilizing, MCR improving, sell-side targets rising into July 16; UNH re-inventing as a tech/software platform ("the Apple of healthcare," ~$3B AI spend, per [Becker's](https://app.matterfact.com/podcasts/4621f0f74c4bd9f6bc1d0d40ca43adaabfd18da0b56b504eb50b7b86024ae01b)).
- *Bear:* Medicaid work requirements, OB3 coverage losses, and regulatory scrutiny (a Massachusetts Medicaid-fraud suit) still cloud the multiple.

## 5. Emerging Themes

- **The "GLP-1 economy" spillover:** protein/fiber, appliances, alcohol/CPG declines and telehealth as a distinct investable basket, not just a pharma story ([The Important Part](https://app.matterfact.com/podcasts/b064a072808cf27b438a8b3e52fa273c75c630214f0c3ceddd2fe406bb9d8a8d)).
- **AI-driven drug discovery and clinical development:** synthetic control arms that "halve enrollment" and save ~$1M/day on Phase 3 ([The Drug Discovery World Podcast](https://app.matterfact.com/podcasts/4009f43912997c66df83e5bb11dca5d180ac1d04ffe10309621c67da7ae839ae)); NVIDIA BioNemo + SandboxAQ virtual screening ([Squawk on the Street](https://app.matterfact.com/podcasts/05799424ef6564c0f37d142d011cbe4c646dfb9c8dac242026616644d3fdc234)).
- **Payer-as-platform:** UnitedHealth monetizing Optum Insight software (claims coding, OR scheduling) and its "COVE" 50M-member command center.
- **Defensive rotation into healthcare:** GMO's Inker frames US large-cap growth as an "AI bubble," underpinning the flow into healthcare/value ([Excess Returns](https://app.matterfact.com/podcasts/86c83dd5e1794873f8f547298821c6e85d5afb9e3f2abdf715d2a4c4849b8999)).

## 6. Deals & M&A Tracker

| Acquirer | Target | Value | Rationale |
| --- | --- | --- | --- |
| AbbVie | Apogee Therapeutics | ~$10.9B (49% premium) | IL-23 blocker for atopic dermatitis; deepens immunology (Skyrizi/Rinvoq) |
| GSK | Nuvalent | ~$10.6B | Precision oncology |
| Sun Pharma | Organon | ~$11.75B | Largest cross-border deal of the year |
| Gilead | Tubulus | n/d | Largest European biotech private sell-side (per JPM) |
| Eli Lilly | Sangamo (assets) | stalking-horse bid | Genomic platforms + prion program; Sangamo in Chapter 11 (Astellas bidding for Fabry) |
| Eli Lilly | Abbisko (collab) | up to ~$1.9B | Multi-target discovery collaboration |
| Innovent | Lilly Verzenios (China) | distribution deal | Innovent takes import/marketing/distribution in mainland China |

Full-year pace: 32 billion-dollar deals / ~$123B YTD, strongest since 2019, per Motley Fool; JPM notes XBI at five-year highs with the largest-ever biotech IPO (Kylara) and follow-on (Revolution Medicines), per [Making Sense](https://app.matterfact.com/podcasts/3ee5627c5cf2b3f27ff8df7eed6633b20525dfb4207b045003e48fb6dc6686ea).

## 7. Regulatory Watch

- **Medicare GLP-1 Bridge (July 1):** first-ever Medicare obesity coverage; $50/month copay; runs through Dec 31, 2027 (temporary). Leerink pegs eventual annual revenue at ~$1B each for Lilly and Novo.
- **Section 301 probe of Germany:** Trump administration targeting Germany's domestic pharma price controls as an "unfair practice"; executives reportedly more worried about the German program than tariffs ([The Trade Guys](https://app.matterfact.com/podcasts/1e1cc0f93067889da1dc78d08db44da74aa69290e99ff97c7822aa4a521d1295)).
- **Most-Favored-Nation pricing:** advancing via voluntary agreements with 17 manufacturers; Section 232 pharma tariffs begin phasing in July 31 (scaling toward a 100% default by September for companies lacking onshoring plans); medical devices currently excluded from Section 232 ([The White House](https://www.whitehouse.gov/), [Sidley](https://www.sidley.com/)).
- **340B / OB3:** HRSA advancing a broader 340B rebate model; the One Big Beautiful Bill Act raises not-for-profit hospital downgrade risk via Medicaid/ACA coverage losses later this decade ([Achieving Health](https://app.matterfact.com/podcasts/38c86377030d67fcd913a59538983809addf9d0a1bc9a4f41dab07e6afbdb584)).
- **Medicaid work requirements:** 25 Democratic-led states + DC sued over CMS's interim final rule ([Becker's](https://app.matterfact.com/podcasts/24c74b7e3351619db72e0bbb822dea7170e3179aa14f786d0c86e06d1d847037)).
- **FDA momentum:** approvals this week included AstraZeneca/Daiichi's T-DXd (early HER2+ breast cancer), Ionis's Tryngolza (guidance raised to $875–900M), GSK/Spero oral tebipenem, and generic baloxavir; rare-disease reversals for uniQure and Regenxbio (resubmitting Q3). Lilly's Lebanon, IN plant selected for the FDA PreCheck manufacturing pilot (6/29).

## 8. Week Ahead

- **July 7:** Vera Therapeutics PDUFA (atacicept, IgA nephropathy).
- **July 16:** UnitedHealth Q2 earnings kick off managed care season; the key test of the margin-recovery thesis (watch the medical care ratio).
- **July 17:** Celcuity PDUFA (gedatolisib, advanced breast cancer).
- **July 24:** Section 122 10% device tariff set to lapse (barring appeal).
- **July 31:** First Section 232 pharma tariffs begin phasing in.
- **Ongoing:** early GLP-1 Bridge uptake data; monitor pill-vs-pill share (Foundayo vs oral Wegovy) and any read-through to Lilly/Novo demand.